Since 2009, the St Gallen consensus panel has suggested that validated multigene signatures may be helpful in deciding whether, in addition to endocrine therapy, adjuvant chemotherapy (CHT) is indicated for women with ER^+^/Her2^−^ early breast cancer. The implementation should occur in cases where its use was uncertain after consideration of conventional markers ([@bib11]).

The 70-gene tumour expression profile MammaPrint (MP) was initially established as a predictor of disease outcome in premenopausal breast cancer ([@bib21]) and was translated into a customised diagnostic breast cancer mini-array, MP, with reliable use in a diagnostic setting ([@bib8]).

A recent independent evaluation of several genomic tests found the available evidence on the analytical and clinical validity of MP to be convincing ([@bib2]). It was shown that in postmenopausal patients at low risk of breast cancer-related death, MP can be of clinical use to accurately select women for adjuvant CHT ([@bib14]).

A community-based observational study confirms the potential of this 70-gene signature to more accurately select breast cancer patients who can forgo adjuvant CHT without compromising outcome. In this study, MP reduced the proportion of high-risk patients as classified by Adjuvant Online by 20% ([@bib6]).

In Austria, endocrine treatment (ET) in the absence of CHT ([@bib13]) even in nodal-positive patients is quite frequent. Several studies of the Austrian breast and colorectal study group showed excellent survival data in both premenopausal ([@bib12]; [@bib9], [@bib10]) and postmenopausal women ([@bib7]) in the absence of adjuvant CHT.

Considering this specific treatment environment that *a priori* leans heavily on endocrine treatment, we asked how a gene expression analysis like MP would change adjuvant CHT treatment decisions. Before the presented study, we performed a retrospective analyses of 27 patients with low- to intermediate-risk ER^+^/HER2^−^ early breast cancer treated in a breast care centre in Upper Austria (Krankenhaus Barmherzige Schwestern Linz, Austria). These data clearly provided valuable data concerning the discordance between molecular and clinical risk assessment (*n*=27; discordance rate: 37%). Unfortunately, we were unable to retrospectively study how molecular *vs* clinical risk assignment alone influences the multidisciplinary team (MDT) decision concerning the recommendation to administer adjuvant CHT. However, this type of decision analysis is important to pinpoint how and when clinicians should implement molecular tests.

In the herein presented study we prospectively included women who lacked clear indications for CHT from conventional markers. In addition, we took the opportunity to compare molecular measurement of hormone receptors, HER-2 and proliferation using immunohistochemistry (IHC) performed at our institution. Finally, in order to evaluate the economic impact of decision changes, a health technology assessment was performed comparing the hypothetical costs arising from decisions made with and without the multigene signature.

Materials and methods
=====================

Ethical and legal aspects
-------------------------

The project was conducted in accordance with the latest revision of the Declaration of Helsinki and the requirements of Good Clinical Practice of the European Community (CPMP/ICH/135/95). The study protocol has been reviewed and approved by the ethics committee of the Medical University of Vienna (EK-No 1116/2009).

Selection of patients and study design
--------------------------------------

After gaining informed written consent, 75 patients with ER-positive, G1 or G2 primary breast carcinomas with a clinical tumour size between 1 and 3 cm and clinically negative lymph nodes were included into the prospective study. Surgery was performed at the Medical University of Vienna over a 2-year period from April 2010 until November 2012. Only patients considered fit for adjuvant CHT treatment were included in this trial. Patients with a triple-negative phenotype at preoperative core needle biopsy or HER-2 overexpression and/or clinical tumour diameter \<1 cm were excluded. Furthermore, stage UICC IV and patients who had undergone preoperative CHT were excluded. Complete resection of all tumour tissue of the breast and regional lymph nodes was mandatory for clinical and molecular risk assignment within the study protocol.

At our institution, between 280 and 300 primary breast cancer patients undergo surgery per year, and hence this study includes ∼8% of all primary breast cancer patients who underwent surgery during this period.

In summary, we analysed a population of women with low to intermediate risk according to the St Gallen criteria 2009 in order to recruit women where the decision to administer adjuvant chemotherapy or not would most likely profit from a further molecular assessment. The study was designed to explore the routine implementation of MP as an additional biomarker into clinical decision making at the MDT level.

Tumour sample collection
------------------------

A tumour tissue sample of at least 3 × 3 × 3 mm was collected within 60 min of surgical removal, placed in the RNA*Retain* (AsuraGen, Austin, TX, USA) molecular fixative and sent to Agendia (Irvine, CA, USA) for Mammaprint and Targetprint analysis. The responsible pathologist adhered to optimal tissue handling techniques in order to preserve tissue quality for histopathological diagnosis.

Methodology in MDT
------------------

Complete patient data including preoperative histology and IHC were subjected to discussion at the Breast Health Care Centre of Vienna (BHCV) MDT according to the local SOP. All data were presented in a strictly standardised format according to BHCV 'Tumour Board Guidelines\'. The MDTs were attended by surgeons, medical oncologists, radiologists, pathologists, radiation oncologists and breast care specialist nurses.

Initial MDT risk stratification decisions (clinical low to high risk) were made in the absence of MP results categorised classically according to pathological features including tumour size, nodal status, grading, IHC of hormone receptors and Ki67. The recommendation of whether or not to deliver adjuvant CHT followed the St Gallen guidelines of 2009 very closely. The later St Gallen guidelines of 2011 were not implemented at BHCV. An MDT risk assessment was performed and a recommendation regarding the addition of CHT to ET was documented.

After obtaining the MP results, the risk stratification and treatment recommendation were repeated and new risk and treatment decisions were recorded.

Histological assessment of IHC and molecular assessment using TargetPrint
-------------------------------------------------------------------------

Histological analysis of ER, PR and HER2 as well as Ki-67 was performed on all tissue samples. All analyses were conducted at the pathologic department of the Medical University of Vienna that also serves as the central pathology in the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Hormone receptor expression was scored as previously described ([@bib15]). Briefly, ER^+^/PgR^+^ indicates the positive staining of 10--50% of tumour cell nuclei; 51--80% corresponds to ER^++^/PgR^++^; and 81--100% of stained nuclei indicate a high degree of hormone receptor expression (ER^+++^/PgR^+++^) ([@bib7]). The Reiner score was calculated according to expression of ER/PR and intensity of the IHC analyses. The assessment of Ki-67 has previously been described ([@bib3]). Briefly, invasive tumour cells in 20 representative HPF ( × 400 magnification) were visually evaluated and only nuclear staining was scored as positive. The results were documented as the percentage of Ki-67-stained nuclei regardless of staining intensity.

MammaPrint and TargetPrint were all performed on fresh tumour samples. Microarray analysis (RNA labelling, microarray hybridisation and scanning) was performed at the centralised Agendia Laboratories blinded for clinical and histological data. RNA was cohybridised with a standard reference to the custom-designed diagnostic chip, each containing oligonucleotide probes for the profiles in triplicate or more ([@bib8]).

The IHC analyses of hormone receptors and Her2neu expression were also correlated with the TargetPrint result. The concordance of the proliferation marker Ki-67 (MIB-1) with MP risk stratification was evaluated.

Cost-effectiveness analysis
---------------------------

In a previous study, a Markov model was constructed with four mutually exclusive health states: disease-free survival, relapse (including local and regional recurrences, secondary primary and contra lateral breast cancer), distant metastases and death. In each strategy, the sensitivity and specificity of the prognostic tests were based on three retrospective validation series ([@bib22]; [@bib5]; [@bib4]). Patients were classified as having a true low, true high, false low or false high risk of developing metastases. The same costs and utilities, to calculate the quality-adjusted life years (QALYs), were applied ([@bib17]).

For the current study, the model simulated the course of events for two prognostic tests: the results after following the MP test and the results after following the clinical decision-making process of the MDT (according to St Gallen guidelines of 2009, as described above). We modelled the noncompliance towards the MP test. In case of noncompliance with a discordant test result, the MP result was available (and paid), but not used in the adjuvant treatment decision. It was assumed that patients would thus be treated according to the MDT assessment. The noncompliance rates towards the MP were modelled for the discordant cases: adjuvant treatment decision according to MDT-assessment low risk/MP high risk (4 out of 8 were discordant, 4 adjuvant decisions were changed; 50% noncompliance) and MDT-assessment high risk/MP low risk (11 out of 21, 10 adjuvant decisions were changed; 52% noncompliance).

Statistical analyses
--------------------

Continuous data were described using median values and ranges (minimum--maximum). Categorical data were described using absolute and relative frequencies. Statistical differences between groups were tested with the *t*-test for normally distributed continuous data or by the Wilcoxon rank-sum test or nonparametric data. Associations between two continuous variables were assessed by Spearman\'s correlation coefficient. *P*⩽0.05 was assumed to be significant. All calculations were performed with SAS (Version 9.2, Cary, NC, USA).

The Markov model for statistical analysis of the cost effectiveness was programmed in Microsoft Excel (Microsoft, Redmond, WA, USA). Future costs and effects were reduced to their present day value by a rate of 4% and 1.5% per annum, respectively. Incremental cost-effectiveness ratios (ICERS) were calculated by dividing the incremental costs by the incremental QALYs. The calculations are performed per year, over a total simulated time period of 20 years.

Results
=======

Demographic data
----------------

A total of 75 patients with hormone receptor-positive, primary, early breast cancer were prospectively included in the study with a mean age of 60 years (min 33, max 86), median tumour size of 1.7 cm (min 0.7, max 10). Nearly 90% of tumours were G1 or G2. In 8 patients (10.7%), a G3 tumour was diagnosed in the final histology report (as opposed to the core needle biopsy used for study inclusion). Approximately one-third of patients had positive lymph node status, of which seven women had more than three positive lymph nodes. In all, 74 patients had an ER^+^ and/or PR^+^ tumour, and in 1 patient overexpression of HER2 was found ([Table 1](#tbl1){ref-type="table"}).

IHC and molecular assessment using TargetPrint and BluePrint
------------------------------------------------------------

All locally assessed IHC results were compared with the TargetPrint assay (both assessing ER/PgR and Her2). There were highly significant correlations between IHC and target prints (ER: *r*~s~=0.47, *P*\<0.0001, PgR: *r*~s~=0.72, *P*\<0.0001, Her2: *r*~s~=0.29, *P*=0.0135). Local IHC analysis of Ki67 also highly correlated with MP results (*P*\<0.0001; [Table 2](#tbl2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}).

According to BluePrint subtyping, 73 patients had luminal-type breast cancer; 1 was HER2 type, and 1 basal type. The patient with HER2-type cancer also exhibited overexpression in our IHC assessment. This patient was included in the study because of a HER2^−^ preoperative biopsy outside of our centre. The patient with the basal-like tumour had a G2 invasive ductal carcinoma with negative ER (0%), positive PR (50%), Her2 0% and Ki-67 of 40%. The MP and clinical assessment were high risk and she received adjuvant CHT.

MammaPrint results and decision change at MDT
---------------------------------------------

In the prospective cohort, 57 (76%) patients were low risk and 18 patients (24%) were high risk according to the 70-gene analyses ([Table 1](#tbl1){ref-type="table"}). In 10 patients (13.3%), there was a decision change towards ET and in 4 patients (5.33%) the MDT decision changed towards the addition of adjuvant CHT ([Table 3](#tbl3){ref-type="table"}), after taking molecular risk into account. In total, 18.6% of women underwent a decision change according to the MDT assessment because of discordant molecular and clinical data.

In a further 15 patients (20%), we found a discordance between clinically assigned risk and MP results. Four patients with a clinical profile determined to be low risk by the MDT showed a high molecular risk according to the MP test. Eleven patients judged to be clinically high risk were found to be of MP low risk. Thus, in 11 women the clinical decision to administer CHT was not amended despite a low molecular risk profile.

In a descriptive analysis we determined the clinical factors that led to CHT administration despite low-risk molecular profile. Five patients were found to have three or more positive lymph nodes in the pathologic report in addition to at least one other relative risk factor. In three women, tumour size was found to be well beyond 3 cm among other risk factors. In the remaining three patients, two women showed a combination of two positive lymph nodes in combination with G2 and high Ki67. Finally, a single patient showed only a G2 tumour with increased proliferation, but her age at diagnosis was 36 years.

In summary, the MP test was able to identify a relevant group of women (*n*=21, 28%) with low molecular risk despite clinical or histological risk factors. In 13.3% overall, this led to a decision change that resulted in the removal of CHT from the MDT recommendation.

Cost-effectiveness analysis
---------------------------

A cost-effectiveness analysis was performed in the prospective population comparing the cost of MP analysis with the amount saved by CHT reduction. The total health-care costs per patient were: €31 696 for MP analysis and €35 475 for MDT assessment. The MP yielded more QALYS (11.97 out of 20 years) compared with MDT assessment (11.24 out of 20 years), showing that the use of MP is more effective and less costly than MDT assessment ([Table 4](#tbl4){ref-type="table"}). In the case of 100% compliance towards the MP test, the MP test was still found to be more effective and less costly (difference in QALYs: 0.32, difference in costs: €554).

Discussion
==========

The aim of our study was to explore the effect of the molecular risk profile MP on the decision making of a MDT in ER^+^/Her2^−^ early breast cancer. Our main focus was to record changes in decision making attributed to risk discordance between the clinical and molecular risk profile. Furthermore, we investigated possible analytical variability between the commercial assays BluePrint and TargetPrint and local immunohistochemistry.

An important finding was the high rate of discordance when comparing molecular and clinical risk. Both a retrospective cohort (data not shown) and the described prospective cohort showed well over one-third of discordant cases (37% and 39%), and this rate is comparable to a similar published case series ([@bib1]). It is conceivable however that analytical variability especially concerning IHC may add to the differential risk assignments. It was therefore reassuring to observe that the gene expression data concerning ER, PGR and Ki-67 were almost identical to our own IHC assessments with highly significant concordance. It is unlikely that differences occurred because of analytical bias between IHC and molecular methods.

Over two-thirds of discordant cases resulted in a downgrade of risk and subsequently led to several MDT decisions without CHT. The protocol for the prospective study foresaw that patients were recruited into the study following clinical assessment and preoperative biopsies. The goal was to preselect patients allowing molecular and full histological data to be discussed without further delay because of shipment and molecular analysis. This led to quite a high percentage of women (16%) who may gain little benefit from a molecular test as they displayed gross lymph node involvement and/or large tumour size and/or poorly differentiated tumours. In these cases, CHT would be indicated in the absence of a molecular assessment -- indeed, in several of these women the test has not been fully validated to have prognostic value. In the future, we recommend that the indication for molecular testing should be withheld until full histological assessment of the surgical specimen is completed. Since completion of the study, MP has been made available for formalin-fixed and paraffin-embedded tissue ([@bib20]).

In comparison with other studies, we had a low number of decision changes at our institution because of a long tradition of ET use in the absence of CHT in ABCSG studies ([@bib13]; [@bib9]). In endocrine-responsive disease, treatment recommendations that exclude CHT (even despite nodal involvement) are more common in Austria than in other European institutions. From the 75 women included in the study, 29 (39%) showed a discordance between their clinical and molecular profile. Interestingly, the MDT changed their decision in only half of these cases (*n*=14). We would suggest three main reasons for this finding. As mentioned above, several women with clear indications for CHT were included in the study and therefore the MDT did not omit CHT from the recommendations in these five cases.

Furthermore, four women deemed to be low risk by the MDT (and in retrospect indeed no relative indication for CHT) showed high-risk molecular signatures. The predictive value of MP regarding the benefit of CHT is questionable and this was the main reason for not adding cytotoxic treatment in these patients. Prospective data from adjuvant trials are much needed in order to answer this question ([@bib19]). Finally, there remains a group of six women where despite adequate prognostic validation of the test and a low-risk molecular profile the MDT recommended CHT -- this possibly shows a certain scepticism towards molecular prognosis. It is noteworthy that these decisions were made during the first months of this study and, for the large majority of clinicians present, reflected their first encounter with a fairly new prognostic biomarker ([@bib6]). In this setting, the cost effectiveness of the MP test was also demonstrated ([@bib16]).

Despite a rigid preselection of clinically low- and intermediate-risk patients, 19% of the patients underwent decision changes because of the molecular signature. Typically, these women displayed risk profiles with one or two discordant pathological variables: for example, Ki-67 may have been clearly elevated but the tumour size was well below 2 cm in the context of high ER, or there was a single positive lymph node with no other risk features present. Although we were able to confirm the cost effectiveness of the MP test ( [@bib17]; [@bib23]; [@bib18]) in our study, implementing gene expression analysis specifically in these types of clinical situations patients may lead to further cost reduction as the impact of molecular scores may be most profound. Furthermore, in treatment environments outside of Austria, a higher proportion of patients may receive CHT after clinical consideration. Thus, again the impact of molecular analysis on cost saving may be larger in these countries.

The main weakness of this study arises from the small sample size. Nevertheless, it provided us with the opportunity to study how medical professionals perceived clinical risk, and how the molecular risk assessment altered this perception on a case-by-case basis. This analysis gives clear insight into how molecular testing should be integrated into clinical decision making. Our study shows that the highest rate of success is likely to be found in women who display intermediate- to high-risk clinical profiles with discordant or inconsistent variables that indicate risk.
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![**Correlation of proliferation (MIB-1) and gene expression analysis MammaPrint (MP).**](bjc2014339f1){#fig1}

###### Patient characteristics

  **Demographic data (*****n*****=75)**                   
  --------------------------------------- --------------- -------
  Mean age in years (±s.d.)                    60±13       
  Median tumour size in cm (min, max)      1.7 (0.7, 10)   
  **Tumour size**                             ***n***     **%**
   T1a                                           0        0
   T1b                                           5        6.7
   T1c                                          44        58.7
  T2                                            21        28
  T3                                             5        6.7
  Invasive ductal carcinoma                     60        80
  Invasive lobular carcinoma                    13        17.3
  Invasive mucinous carcinoma                    2        2.7
  **Grading**                                             
   G1                                           27        36
   G2                                           40        53.3
   G3                                            8        10.7
  **Lymph nodes**                                         
   N0                                           48        64
   N1                                           20        26.7
   N2/N3                                         7        9.3
  PVI                                           22        29.3
   ER+                                          74        98.7
   Her2neu+                                      1        1.3
  **Ki-67**                                               
   10%                                          26        34.7
   15--25%                                      27        36
   \>30%                                        22        29.3
  MammaPrint high risk                          18        24
  MammaPrint low risk                           57        76
  Luminal                                       73        97.3
  Basal                                          1        1.3
  ERB2                                           1        1.3

Abbreviations: ER=oestrogen receptor; PVI=perivascular invasion.

###### Concordance of TargetPrint and immunohistochemistry

                                                     **Spearman\'s correlation**  ***P*****-value**
  ------------------------------------------------- ----------------------------- -------------------
  Oestrogen receptor: Reiner score TargetPrint                  0.471             \<0.0001
  Progesterone receptor: Reiner score TargetPrint               0.715             \<0.0001
  Her2neu− TargetPrint                                          0.294             0.0135
  **Correlation of MIB-1 and MammaPrint**                                         
                                                        **Median (min, max)**     ***P*****-value**
  Low risk                                                   20 (5--50)           \<0.0001
  High risk                                                  30 (10--80)           

###### Decision change at multidisciplinary team (MDT)

  **Clinical risk assignment**   **Molecular risk assignment**   ***n***   **Decision change**
  ------------------------------ ------------------------------- --------- ---------------------
  Clinically low risk            MammPrint low risk              36        0
  Clinically low risk            MammaPrint high risk            8         4
  Clinically high risk           MammPrint low risk              21        10
  Clinically high risk           MammaPrint high risk            10        0

###### Cost effectiveness

                                           **Clinically low**                                                 **Clinically high**                           **Total**
  ---------------- ------------------------------------------------------------------ -------------------------------------------------------------------- -----------
  **MammaPrint**                                                                                                                                           
  Low                                              36                                  21 (wherefrom 10 × change to ER, and 11 × noncompliant towards MP)      57
  High              8 (wherefrom 4 × change to CHT, and 4 × noncompliant towards MP)                                   10                                      18
  Total                                            44                                                                  31                                      75

  **Results**                                                        
  ------------- --------- ------- -------- ------ -------------------------------------
  MammaPrint     €31 696  11.97    −€3779  0.73    Dominant[a](#t4-fn2){ref-type="fn"}
  Clinically     €35 475  11.24                                      

Abbreviations: CHT=chemotherapy; ER=oestrogen receptor; ICER**=**incremental cost-effectiveness ratio; MP=MammaPrint; QALY=quality-adjusted life years.

Dominant: the MP is less costly and more effective compared with the clinical strategy.
